RAINFO LEXICON
Abbreviations and Acronyms
NOTE: This is a work-in-progress.
Send additions and corrections to the webmaster.
|
120-day Safety Report |
Amendment to a NDA due 120 days after the NDA is filed that contains a safety update. |
|
30-day hold |
Time period between filing a protocol under an IND and FDA OK to proceed with enrollment. |
|
510(k) |
Premarket Notification Submission (United States) |
|
510(k) |
A premarket notification submitted to FDA to demonstrate that the medical device to be marketed is as safe and effective or substantially equivalent to a legally marketed device. 510(k) refers to the section of the FD&C Act authorizing the submission of the premarket notification. |
|
510K |
Premarket Notification Submission (United States) |
|
AAA |
Abdominal Aortic Aneurysm |
|
AAAS |
American Association for the Advancement of Science |
|
AABB |
American Association of Blood Banks |
|
AACC |
American Association for Clinical Chemistry (United States) |
|
AADA |
Abbreviated Antibiotic Drug Application (primarily used for generics) |
|
AAHP |
American Association of Health Plans (United States) |
|
AAMI |
Association for the Advancement of Medical Instrumentation (United States) |
|
AAPS |
American Association of Pharmaceutical Scientists |
|
Abbreviated 510(k) |
submission based on guidance document(s); special controls or standards. |
|
ABHI |
Association of British Health Care Industries (United Kingdom) |
|
ABIMO |
Medical device trade association (Brazil) |
|
ABPI |
Association of the British Pharmaceutical Industry (United Kingdom) |
|
ACC |
American College of Cardiology (United States) |
|
ACE |
Adverse Clinical Event |
|
ACGIH |
American Conference of Governmental Industrial Hygienists (United States) |
|
ACII |
American Standard Code for Information Exchange (United States) |
|
ACNP |
American College of Nuclear Physicians (United States) |
|
ACR |
American College of Radiology (United States) |
|
ACRP |
American Clinical Research Professionals (United States) |
|
ACS |
American Chemical Society |
|
Action Letter |
Official communication of FDA informing NDA sponsor of an agency decision. Includes approvable, not approvable, clinical hold and warning letters. |
|
Active Ingredient |
Any drug component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals. |
|
ADA |
American Dental Association (United States) |
|
ADA |
Americans with Disabilities Act (United States) |
|
ADDM |
Association of Disposable Device Manufacturers |
|
ADE |
Adverse Drug Event, or Adverse Drug Experience |
|
ADME |
Absorption, distribution, metabolism, and elimination (of a drug) |
|
ADME |
Absorption, Distribution, Metabolism, and Excretion |
|
ADP |
Automated Data Processing |
|
ADR |
Adverse Drug Reaction |
|
ADR |
Adverse Drug Reaction |
|
ADRAC |
(Australia) |
|
Adulterated |
Product is not made according to GMPs or is contaminated. |
|
AE |
Adverse Event |
|
AER |
Adverse Event Report |
|
AERS |
Adverse Events Reporting System |
|
AERS |
Adverse Event Reporting System |
|
AESGP |
An OTC industry association in Europe |
|
AETSA |
Agencia de Evaluación de Tecnologias Sanitarias de Andalucia (Spain) |
|
AFDO |
Association of Food and Drug Officials |
|
AFSSAPS |
Agence Française de Sécurité Sanitaire des Produits de Santé (France) |
|
AGIM |
Belgian industry association (pharmaceuticals) |
|
AGRD |
(Australia) |
|
AGRF |
Australian Genome Research Facility |
|
AHCPR |
Agency for Health Care Policy and Research |
|
AHCPR |
Agency for Health Care Policy and Research (obsolete, use AHRQ) |
|
AHRQ |
Agency for Healthcare Research and Quality (pronounced “arc”) |
|
AIC |
Adverse Incident Centre (United Kingdom - MDA) |
|
AIDS |
Acquired Immune Deficiency Syndrome |
|
AIMD |
Active Implantable Medical Device |
|
AIMDD |
Active Implantable Medical Device Directive
|
|
AIP |
Application Integrity Policy: the policy contains the agency’s approach regarding the review of applications that may be affected by wrongful acts that raise significant questions regarding data reliability. |
|
AIUM |
American Institute of Ultrasound in Medicine (United States) |
|
AMA |
American Medical Association |
|
AMDM |
Association of Medical Device Manufacturers (Hungary) |
|
AMDR |
Association of Medical Device Reprocessors |
|
Amendment |
Additions or changes to a NDA, PMA or PMA supplement still under review. Includes safety updates. |
|
ANADA |
Abbreviated New Animal Drug Application (United States) |
|
ANADA |
Abbreviated New Animal Drug Application |
|
ANAES |
Medical technology evaluation agency (France) |
|
ANDA |
Abbreviated New Drug Application (United States- FDA) |
|
ANDA |
Abbreviated New Drug Application (used for generic drugs) |
|
ANIMAT |
Administración Nacional de Medicamentos, Alimentos y Tecnologia Médica (Argentina) http://www.anmat.gov.ar/principal.html |
|
ANMV |
French national veterinary medicines agency |
|
Annual report |
An annual report to an active IND is required. Summaries of preclinical and clinical investigations, safety reports not previously filed and updates to CMC information are included. Report to be submitted by manufacturers of radiation emitting devices. Report to be submitted by sponsors of IDEs to IRBs and FDA (also called Progress Report). |
|
ANOM |
Analysis of Means |
|
ANOVA |
Analysis of Variance |
|
ANPR |
Advance Notice of Proposed Rulemaking (United States) |
|
ANSI |
American National Standards Institute (United States) |
|
ANVS |
Agencia
Nacional de Vigilancia Sanitaria (National Agency of Health
Surveillance) |
|
APA |
American Psychiatric Association (United States) |
|
APA |
American Pharmaceutical Association |
|
APB |
Pharmacist's association (Belgium) |
|
APhA |
American Pharmaceutical Association |
|
APHIS |
Animal and Plant Health Inspection Service |
|
API |
Application Program Interface |
|
API |
Active Pharmaceutical Ingredient |
|
API |
Active Pharmaceutical Ingredient |
|
APIFARMA |
Portugal |
|
Approved |
FDA designation given to drugs, biologics and medical devices that have approved marketing applications (NDA, BLA or PMA). |
|
AQL |
Acceptable Quality Level |
|
ARC |
AIDS Related Complex |
|
ARC |
American Red Cross (United States) |
|
ARTG |
Australian Register of Therapeutic Goods |
|
ASA |
Acoustical Society of America (United States) |
|
ASM |
American Society for Microbiology |
|
ASME |
American Society of mechanical Engineers (United States) |
|
ASQ |
American Society for Quality (formerly ASQC) |
|
ASR |
Analyte Specific Reagent (United States - FDA) |
|
ASTM |
American Society for Testing and Materials (United States) |
|
ATCC |
American Type Culture Collection (United States) |
|
ATF |
Bureau of Alcohol, Tobacco and Firearms |
|
AUA |
Authorised User Access (Australia) |
|
AUC |
Area Under the Curve |
|
AUST L |
Numbering scheme for Australian conformity mark |
|
AUST R |
Numbering scheme for Australian conformity mark |
|
AV |
Atrioventricular |
|
B/F |
Bacteriostasis/Fungistasis (USP) |
|
BACPAC |
Bulk Activities Post Approval Changes (United States - FDA) |
|
BACPAC |
Bulk Actives Post Approval Changes |
|
BAH |
German medicines manufacturers association |
|
BAH |
OTC association (Germany) |
|
Banned Device |
A device that presents a substantial deception, unreasonable risk of injury or illness, or unreasonable direct and substantial danger to the public health. |
|
BEI |
Biological Exposure Indicies |
|
BfArM |
Federal Institute for Drugs and Medical Devices (Germany) http://www.bfarm.de/gb_ver/ |
|
BHF |
Batch History File |
|
BHR |
Batch History Record |
|
BiMo |
Bioresearch Monitoring (United States - FDA) |
|
BIO |
Biotechnology Industry Organization |
|
Biologic |
Any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment or cure of diseases or injuries in man. |
|
BIRA |
British Institute of Regulatory Affairs |
|
BL |
Biologics License (United States) |
|
BLA |
Biologics License Application (United States - FDA) |
|
BLA |
Biologics License Application (replaces PLA/ELA) |
|
Blinded Study |
Clinical trial where the patient (single-blind) or patient and investigator (double-blind) are unaware of which treatment the patient receives. Involves use of multiple treatment groups such as other active, placebo or alternate dose groups. Sometimes termed “Masked.” |
|
BMA |
British Medical Association (UK) |
|
BMJ |
British Medical Journal (UK) |
|
BPI |
German industry association of small- and medium-sized pharmaceutical companies in Germany |
|
BSE |
Bovine Spongiform Encephalopathy |
|
BVmed |
German medical device industry association http://www.bvmed.de |
|
CA |
Certification Authority |
|
CA |
Competent Authority |
|
CA |
Competent Authority Governmental agency in each EC member state responsible for monitoring and enforcing the MDD. |
|
CAB |
Conformity Assessment Body |
|
CAB |
Conformity Assessment Body (EU) |
|
CABG |
Coronary Artery Bypass Graft |
|
CAD |
Computer Aided Design |
|
CADREAC |
Collaboration Agreement of Drug Regulatory Authorities of EU-associated Countries |
|
CAE |
|
|
CAM |
|
|
CANDA |
Computer Assisted New Drug Application (obsolete) |
|
CANDA |
Computer Aided New Drug Application (United States) |
|
CAP |
College of American Pathologists (United States) |
|
CAPA |
Corrective and Preventive Actions |
|
CAPLA |
Computer Assisted Product License Application (obsolete) |
|
CAPLA |
Computer Aided Product License Application (United States) |
|
CAPRA |
Canadian Association of Professional Regulatory Affairs |
|
CAS |
|
|
CBE-30 |
Changes Being Effected within 30 days (applies to manufacturing changes) |
|
CBER |
Center for Biologics Evaluation and Research |
|
CBER |
Center for Biological Evaluation and Research (United States - FDA) |
|
CCITT |
Committe Consultatif International Telegraphique et Telephonique |
|
CCMA |
Certified Color Manufacturer’s Association |
|
CDC |
Centers for Disease Control and Prevention |
|
CDC |
Centers for Disease Control and Prevention (United States) |
|
CDER |
Center for Drug Evaluation and Research |
|
CDER |
Center for Drugs Evaluation and Research (United States - FDA) |
|
CDRH |
Center for Devices and Radiological Health |
|
CDRH |
Center for Devices and Radiological Health (United States - FDA) |
|
CE |
Cost Effectiveness |
|
CE |
Conformity mark (EU) |
|
CE Mark |
Mark signifying compliance with applicable European Community directive (e.g., MDD, IVDD, or AIMDD). |
|
CEEC |
Central and Eastern European Countries (Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia) |
|
CEN |
Comite Europeen de Normalisation (European Committee of Standardization) - European Committee for Satndardization (EU) |
|
CENELC |
|
|
CENELEC |
|
|
CEO |
Chief Executive Officer |
|
CF |
Consent Form (document used to inform a potential subject of the risks and benefits of a clinical trial) |
|
CFG |
Certificate to Foreign Government (Required by certain countries to prove that exported product is being manufactured to the requirements of GMPs; provided by FDA for export of legally marketed devices.) |
|
CFI |
Court of First Instance (EU) |
|
CFO |
Chief Financial Officer |
|
CFR |
Code of Federal Regulations |
|
CFR |
Code of Federal Regulations (United States) |
|
CFSAN |
Center of Food Safety and Applied Nutrition |
|
CFSAN |
Center for Food Safety and Nutrition (United States - FDA) |
|
CFU |
Colony Forming Unit |
|
CGMP |
Current Good Manufacturing Practice |
|
CGMP |
Current Good Manufacturing Practices (United States - FDA) |
|
CGMP |
Current Good Manufacturing Practice |
|
CGSB |
Canadian General Standards Board (Canada) |
|
CH |
Clinical Hold |
|
CHPA |
Consumer Health Products Association |
|
CIAA |
Confederation of the EU Food and Drink Industry |
|
CIE |
International Commission on Illumination |
|
CIO |
Chief information Officer |
|
CIOMS |
Council for International Organizations of Medical Sciences (The CIOMS form may be used for post-approval international AE reporting.) |
|
CIOMS |
(Australia) |
|
CISPR |
|
|
Class I Device |
Low risk device requiring general controls to assure safety and effectiveness. |
|
Class II Device |
Requires general and special controls to ensure S&E. Special controls may include mandatory performance standards, patient registries for implantable devices, and postmarket surveillance. Requires 510(k) unless exempted. May require clinical trials. |
|
Class III Device |
Requires general controls, special controls, and PMA; includes devices that are life sustaining, life supporting or pose potential risk to patient. PMA may require clinical trials. |
|
Clearance |
Devices that receive permission to market, not approval. Designation based on demonstrating substantial equivalence to a preamendment device or another device reviewed under section 510(k) of the FD&C Act. |
|
CLIA |
|
|
CLIAC |
|
|
Clinical Hold |
FDA order to delay proposed clinical investigation or to suspend an ongoing investigation. |
|
CMA |
Central Medicines Authority |
|
Cmax |
Concentration at maximum |
|
CMC |
Chemistry, Manufacturing and Controls |
|
CMC |
Chemistry, Manufacturing and Controls (US FDA/CDER and CBER) |
|
CMCCC |
Chemistry Manufacturing Controls Coordinating Committee (United States - FDA - CDER) |
|
CME |
Continuing Medical Education |
|
CMS |
Centers for Medicare and Medicaid Services |
|
CMS |
|
|
CNAM |
Caisse natiuonale de l'assurance maladie (French public health insurance agency) |
|
COCIR |
Radiological and electromedical industry association |
|
COE |
Certificate of Exportability (Is required by certain countries for the export of unapproved devices not sold or offered for sale in the United States; issued by FDA to the exporter.) |
|
CofA |
Certificate of Analysis |
|
Commercial Distribution |
Any distribution of a device intended for human use, which is offered for sale but does not include: internal or interplant transfer within the same parent, subsidiary or affiliate company; or any device with an approved exemption for investigational use. |
|
Compassionate Use IND |
(obsolete) see Treatment IND |
|
Complaint |
Any written, electronic or oral communication alleging deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a product after release for distribution. |
|
Component |
Any ingredient/part intended for use in the manufacture of a drug, device, cosmetic, biologic or IVD product, including those that may not appear in the finished product. |
|
COO |
Chief Operating Officer |
|
COSHH |
Control of Substances Hazardous to Health (UK) |
|
Cosmetic |
Articles intended to be rubbed, poured, sprinkled or sprayed on, introduced into or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractive- ness or altering appearance; and Articles intended for use as a component of any such article; except that such term shall not include soap. |
|
COSTART |
Coding Symbols for a Thesaurus of Adverse Reaction Terms (Used to code AE’s to standard preferred terms and body systems-will be replaced by MedDRA.) |
|
CPAC |
Central Pharmaceutical Affairs Council (Japan - NIHS) |
|
CPAP |
Continuous Positive Airway Pressure |
|
CPG |
Compliance Policy Guide (US FDA) |
|
CPMP |
Committee for Proprietary Medicinal Products (Europe) |
|
CPMP |
Committee for Proprietary Medicinal Products (EU) |
|
CPS |
Crown Prosecution Service (UK) |
|
CPSC |
Consumer Product Safety Commission |
|
CPSC |
Consumer Product Safety Commission (US) |
|
CRA |
Clinical Research Associate |
|
CRADA |
Cooperative Research and Development Agreement (with NIH) |
|
CRADA |
|
|
CRC |
Clinical Research Coordinator |
|
CRF |
Case Report Form (Used to record data collected in a clinical trial.) |
|
CRO |
Contract Research Organization |
|
CRT |
Cathode Ray Tube |
|
CSA |
Canadian Standards Association |
|
CSF |
Cerebral Spinal Fluid |
|
CSM |
Committee on Safety Of Medicines (United Kingdom) http://www.open.gov.uk/mca/csmhome.htm |
|
CSO |
Consumer Safety Officer (Usually the contact person for Sponsors at FDA. Also known as the project manager.) |
|
CT |
Controlled Trials (Australia) |
|
CTD |
Common Technical Document |
|
CTD |
Common Technical Document |
|
CTE |
Clinical Trial Exemption (Australia) |
|
CTFA |
Cosmetic, Toiletry & Fragrance Association |
|
CTN |
Clinical Trial Notification (Australia) |
|
CTX |
Clinical Trial Exemption (Europe). (Permission to ship drug for investigational purposes; equivalent to IND.) |
|
CUF |
Italian drug committee |
|
Custom Device |
is not generally available in finished form for purchase or dispensing by prescription; is not offered for commercial distribution through labeling or advertising; is intended for use by an individual patient named in the order of a physician or dentist, and is to be made in a specific form for that patient; is intended to meet the special needs of the physician or or dentist. |
|
CV |
Coefficient of Variation |
|
CVM |
Center for Veterinary Medicine |
|
CVM |
Center for Veterinary Medicine (United States - FDA) |
|
CVMP |
Committee for Veterinary Medicinal Products (EU) |
|
CZE |
Capillary Zone Electrophoresis |
|
D&D |
Design and Development Plan |
|
DA |
Designated Authority |
|
DAMOS |
|
|
DB |
Device Bulletin (UK - MDA) |
|
DCGI |
Drug Controller General of India |
|
DCLD |
Division of Clinical Laboratory Devices (US - FDA - CDRH - ODE) |
|
DDE |
Department of Drug Evaluation (Korea) |
|
DDMAC |
Division of Drug Marketing, Advertising, and Communications |
|
DDR |
Department of Medicinals Devices & Radiation Health (Korea) |
|
DEA |
Drug Enforcement Administration |
|
Debarment |
An action against an individual restricting him/her from directly or indirectly providing services in any capacity to a firm with an approved or pending drug/device product application. A debarred corporation is prohibited from submitting or assisting in the submission of any NDA or ANDA (disqualification for devices PMA submission). |
|
Declaration of Helsinki |
Ethical principles for medical research involving human subjects. Trials conducted under GCP generally follow the Declaration of Helsinki. |
|
DEP |
Device Evaluation and Publications (UK - MDA) |
|
DES |
Data Encryption Standard |
|
DESI |
Drug Efficacy Study Implementation |
|
DFA |
Department of Food Additives Evaluation (Korea) |
|
DFE |
Department of Food Evaluation (Korea) |
|
DG III |
EC Commission's Directorate General for Industry |
|
DG III-E-3 |
Pharmaceuticals and Cosmetics Unit of DG III |
|
DG IV |
Agriculture |
|
DG V |
|
|
DG XXIV |
Consumer |
|
DHF |
Design History File (Describes the design of a finished device.) |
|
DHF |
Design History File |
|
DHHS |
Department of Health and Human Services |
|
DHHS |
Department of Health and Human Services (United States) |
|
DHR |
Device History Record. (Contains the production history of a device.) |
|
DI |
Distilled |
|
DIA |
Drug Information Association |
|
DIA |
Drug Information Association (United States) |
|
DIMDI |
German Institute for Medical Documentation and Information (for EU devices database) |
|
DIN |
Deutsches Institute fur Normung (Germany) |
|
DMDA |
Danish industry association for medical devices |
|
DMEPOS |
Durable Medical Equipment, Prosthetics and Orthotics |
|
DMF |
Drug Master File (A Drug Master File is a submission to FDA that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging and storing of one or more human drugs.) |
|
DMF |
Drug Master File (United States) FDA) |
|
DMR |
Device Master Record (A compilation of records containing the procedures and specifications for a finished device.) |
|
DNA |
|
|
DNB |
Department of Natural Medicinals & Biologics Evaluation (Korea) |
|
DNM |
Department of National Medicinals (Korea) |
|
DOE |
Department of Energy (United States) |
|
DOE |
Design of Experiments |
|
DOH |
Department of Health (United Kingdom) |
|
DOPA |
Department of Pathology (Korea - NITR) |
|
DOPH |
Department of Pharmacology (Korea - NITR) |
|
DOT |
Department of Toxicology (Korea - NITR) |
|
DOT |
Department of Transportation (United States) |
|
DP |
Department Procedure |
|
DPI |
Dry Powder Inhaler |
|
DRA |
Drug Regulatory Affairs |
|
DRA |
Drug Regulatory Authority (EMEA) |
|
DRG |
Diagnosis related group |
|
DRGs |
Diagnosis related groups |
|
Drug |
Any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man. |
|
Drug Product |
A finished dosage form (e.g., tablet, capsule, solution, etc.) that contains an active drug ingredient generally, but not necessarily, associated with inactive ingredients. This also includes a finished dosage form that does not contain an active ingredient but is intended to be used as a placebo. |
|
DSEB |
Drug Safety Evaluation Branch (Australia) |
|
DSMA |
Division of Small Manufacturers Assistance (US - FDA) |
|
DSMB |
Data and Safety Monitoring Board |
|
DSMB |
Data Safety Monitoring Board (US) |
|
DSS |
Digital Signature System |
|
DTC |
Direct-to-Consumer (drug advertising) |
|
DTC |
Direct-to-consumer (UK) |
|
DTD |
Document Type Definition |
|
DTI |
Department of Trade and Industry (UK) |
|
DTS1 |
Device Technology & Safety Section 1 - Sterile, Surgical and In vitro Diagnostic Devices (UK - MDA) |
|
DTS2 |
Device Technology & Safety Section 2 - Rehabilitation and Transfer Equipment (UK - MDA) |
|
DTS3 |
Device Technology & Safety Section 3 - Wheelchairs and associated Seating/Supports (UK - MDA) |
|
DTS4 |
Device Technology & Safety Section 4 - Diagnostic Imaging, Surgery & Therapy, Physiological Measurement, Audiology and Disability Equipment (UK - MDA) |
|
DTS5 |
Device Technology & Safety Section 5 - Critical Care Devices (UK - MDA) |
|
DTS6 |
Device Technology & Safety Section 6 - Implants and Materials (UK - MDA) |
|
EA |
Environmental Assessment |
|
EBAF |
Endometrial Bleeding Associated Factor |
|
EBM |
German doctors' fee schedule |
|
EBXL |
Electron Beam Cross Linking |
|
EC |
European Commission, European Community or Ethics Committee |
|
EC |
European Community |
|
ECG |
Electrocardiogram |
|
ECHR |
European Convention on Human Rights |
|
ECHTA |
European Co-ordination for Health Technology Assessment |
|
ECJ |
European Court of Justice (EU) |
|
ECO |
Emergency Change Order |
|
ECOFIN |
|
|
ECOSOC |
EC Economic and Social Committee (EU) |
|
ECPHIN |
European Community Pharmaceutical Information Network (ETOMEP) http://www.jrc.org/isis/etomep/activities/ecphin.asp |
|
ECRI |
|
|
ED |
Erectile Dysfunction |
|
EDI |
Electronic Data Interchange |
|
EDIFACT |
Electronic Data Interchange for Administration, Commerce and Transport (United Nations) |
|
EDMA |
European Diagnostics Manufacturers Association |
|
EEA |
European Economic Area |
|
EEC |
|
|
EEG |
Electroencephalograph |
|
EFOIA |
Electronic Freedom of Information Act (United States) |
|
EFPIA |
European Federation of Pharmaceutical Industry Associations |
|
EFTA |
European Free Trade Association |
|
EFTA |
European Free Trade Area |
|
EG |
Expert Group |
|
EGA |
European Generics medicines Association |
|
EIR |
Establishment Inspection Report |
|
EL |
Establishment License (United States) |
|
ELA |
Establishment License Application (obsolete, use BLA) |
|
ELA |
Establishment License Application (United States) |
|
EMBS |
Engineering in Medicine and Biology Society (United States) |
|
EMC |
Electromagnetic Compatibility |
|
EMEA |
The European Agency for the Evaluation of Medicinal Products |
|
EMEA |
European Medicines Evaluation Agency (EU) http://www.eudra.org/emea/emea.html |
|
Emergency Use IND |
FDA authorization of shipment of drug for a specific emergency use for life-threatening or serious disease with no alternative treatment. |
|
EMI |
Electromagnetic Interference |
|
EN |
|
|
EO |
Ethylene Oxide |
|
EP |
European Parliment |
|
EPA |
Environmental Protection Agency |
|
EPA |
Environmental Protection Agency (US) |
|
EPAR |
European Pharmaceutical Assessment Report |
|
EPO |
European Patent Office (EU) |
|
ERA |
European and Regulatory Affairs (UK - MDA) |
|
ERA |
European Regulatory Affairs (journal) |
|
ESD |
Electrostatic Discharge Association (US) |
|
ESD |
Electrostatic Discharge |
|
ESRA |
|
|
ESTRI |
Electronic Standards for Transmission of Regulatory Information |
|
EtO |
Ethylene Oxide |
|
ETO |
Ethylene Oxide |
|
ETOMEP |
European Technical Office for Medicinal Products http://www.jrc.org/isis/etomep/index.asp#top |
|
EU |
European Union (15 Member States: Belgium, Germany, France, Italy, Luxembourg, the Netherlands, Denmark, Ireland, the United Kingdom; Greece; Spain, Portugal; Austria, Finland and Sweden) |
|
EU |
European Union |
|
EUCOMED |
European medical device trade association |
|
EUDAMED |
EC Medical Device Database |
|
EUDRA |
|
|
EVG |
Endovascular Graft (ISCVS) |
|
Expected Life |
Time a device is expected to remain functional after placement into service. |
|
Expiration Date |
Date printed on label of product indicating the end of the useful life. Length of expiration period determined by stability studies and negotiated with FDA for drugs and IVDs. |
|
FAR |
Field Alert Report |
|
Farmindustria |
Italian industry association |
|
Fast Track |
Accelerated NDA and review. Allows surrogate endpoint. |
|
FCC |
Federal Communications Commission |
|
FCC |
Federal Communications Commission (United States) |
|
FD&C Act (FDCA) |
Federal Food, Drug and Cosmetic Act (also abbreviated as FFDCA) |
|
FDA |
Food and Drug Administration |
|
FDA |
Food and Drug Administration (United States) |
|
FDAMA |
FDA Modernization Act of 1997 |
|
FDAMA |
FDA Modernization Act of 1997 (United States) |
|
FDC |
Food Drug and Cosmetic (United States) |
|
FDERA |
FDA Expert Reform and Enhancement Act of 1996 |
|
FDLI |
Food and Drug Law Institute |
|
FDP |
Fibrin/Fibrinogen Degradation Products |
|
FEFANA |
A European feed additive industry association |
|
FFDCA |
Federal Food, Drug, and Cosmetic Act |
|
FIFRA |
Federal Insecticide, Fungicide and Rodenticide Act (United States) |
|
FMEA |
Failure Modes and Effects Analysis |
|
FMECA |
Failure Mode, Effects and Critical Analysis |
|
FOI |
Freedom of Information |
|
FOIA |
Freedom of Information Act |
|
FOIA |
Freedom of Information Act (United States) |
|
FPLA |
Fair Packaging and Labeling Act |
|
FQPA |
Food Quality Protection Act of 1996 (US) |
|
FR |
Federal Register |
|
FR |
Federal Register (United States) |
|
FSPF |
French pharmacists association |
|
FTA |
Fault Tree Analysis |
|
FTC |
Federal Trade Commission |
|
FTP |
File Transfer Protocol |
|
FY |
Fiscal Year (United States) |
|
GAO |
General Accounting Office |
|
GAO |
Government Accounting Office (United States) |
|
GATT |
General Agreement on Tariffs and Trade |
|
GB |
Gigabyte |
|
GC |
General Counsel (FDA) |
|
GC |
Gas Chromatography |
|
GC/MS |
Gas Chromatography/Mass Spectrometry |
|
GCP |
Good Clinical Practice (Refers to the regulations and requirements that must be complied with while conducting a clinical study. These regulations apply to the manufacturers, sponsors, clinical investigators, institutional review boards and the medical device.) |
|
GCP |
Good Clinical Practice |
|
GCPs |
Good Clinical Practices |
|
Generic Drug |
Drugs manufactured and approved after the original brand name drug has lost patent protection. Marketing approval filed with ANDA. |
|
GGP |
Good Guidance Practice (United States) |
|
GHTF |
Global Harmonization Task Force http://www.ghtf.org |
|
GI |
Gastrointesinal |
|
GINC |
Global Information Network on Chemicals |
|
GLP |
Good Laboratory Practice (Refers to nonclinical laboratory studies that support or are intended to support applications for research or marketing permits.) |
|
GLP |
Food Laboratory Practice (Australia) |
|
GLP |
Good Laboratory Practices (United States) |
|
GMC |
Genetically Modified Crop |
|
GMDN |
Global Medical Device Nomenclature |
|
GMO |
Genetically Modified Organism |
|
GMP |
Good Manufacturing Practice (for devices, see Quality System Regulation 1997) |
|
GMP |
Good Manufacturing Practice |
|
GMPs |
Good Manufacturing Practices |
|
GPO |
Group Purchasing Organization (United States) |
|
Grandfathered |
Drugs on the market before 1938. Devices on the market before 1976. |
|
GRAS(E) |
Generally Recognized as Safe (and Effective) |
|
GRP |
Good Review Practice |
|
GRP |
Good Regulatory Practices |
|
Guidance |
Documents published by FDA to provide interpretation of regulations. |
|
Guidance |
Documents published by FDA to provide interpretation of regulations. |
|
HA |
Hyaluronic Acid |
|
HACCP |
Hazard Analysis and Critical Control Point (inspection technique) |
|
HACCP |
Hazard Analysis Critical Control Points (United States - FDA) |
|
HCFA |
Health Care Financing Administration (determines Medicare payment system) (obsolete, use CMS) |
|
HCFA |
Health Care Financing Administration (United States) |
|
HCT |
Hematocrit |
|
HDC |
High Density Collagen |
|
HDE |
Humanitarian Device Exemption |
|
HDE |
Humanitarian Device Exemption (United States - FDA) |
|
HDPE |
High density polyethylene |
|
HEPA |
|
|
HHS |
Health and Human Services (Department of) |
|
HHS |
Health and Human Services (United States) |
|
HIMA |
Health Industry Manufacturers Association (United States) now called "AdvaMed" |
|
HIV |
Human Immunodeficiency Virus |
|
HL7 |
Health Level 7 (an ANSI standard used to facilitate the electronic interchange of data in a healthcare environment) |
|
HLC |
Healthcare Leadership Council (United States) |
|
HMD |
Head Mounted Display |
|
HMO |
Health Maintenance Organization |
|
HMO |
Health Maintenance Organization (US) |
|
HN |
Hazard Notice (UK - MDA) |
|
HPB |
Health Protection Branch (Canada’s equivalent of FDA) |
|
HPB |
Health Protection Branch (Canada) |
|
HSE |
Health and Safety Executive (UK) |
|
HTLV |
Human T-Cell Lymphotropic Virus |
|
HTML |
Hypertext Markup Language |
|
HTTP |
Hypertext Transfer Protocol |
|
HUD |
Humanitarian Use Device |
|
I/O |
Input/Output |
|
IB |
Investigator’s Brochure |
|
IC |
Informed Consent |
|
IC |
Informed Consent (United States) |
|
ICH |
International Conference on Harmonization (participants include Europe, Japan and US) |
|
ICH |
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
|
ICSR |
Individual Case Safety Report |
|
IDE |
Investigational Device Exemption |
|
IDE |
Investigational Device Exemption or Investigational Device Exemption Application (United States - FDA) |
|
IDMC |
Independent Data Monitoring Committee |
|
IDN |
Integrated Delivery Network |
|
IDSMB |
Independent Data Safety Monitoring Board |
|
IEC |
International Electrotechnical Commission |
|
IEEE |
Institute of Electrical and Electronic Engineers |
|
IES |
Illuminating Engineering Society (US) |
|
IESNA |
|
|
IEST |
Institute of Environmental Sciences and Technology |
|
IFPMA |
International Federation of Pharmaceutical Manufacturers Associations |
|
IG |
Inspector General (US) |
|
IHC |
Immunohistochemistry reagents (US - FDA) |
|
IKS |
Interkantonale Kontrollstelle für Heilmittel - Intercantonal regulatory body (Switzerland) |
|
IMB |
Irish Medicines Board (Ireland) |
|
IMDA |
Independent Medical Distributors Association (US) |
|
IMDRM |
International Medical Device Regulatory Monitor (journal) |
|
IMRT |
Intensity Modulated Radiation Therapy |
|
Inactive Ingredient |
Any component of a drug product other than an active ingredient such as excipients, vehicle and binders. |
|
INAD |
Investigational New Animal Drug |
|
INAMI |
Belgian health insurance body |
|
IND |
Investigational New Drug (application) |
|
IND |
Investigational New Drug or Investigational New Drug Application (United States - FDA) |
|
INDOMED |
Indian Device Industry Group |
|
INFARMED |
Instituto Nacional da Farmácia e do Medicamento (Portugal) http://www.infarmed.pt/home.html (in Portuguese) |
|
Information Amendment |
Includes most submissions under an active IND, such as new protocols, final study reports, safety reports, CMC information, etc. The initial IND is number 000 and each subsequent serial amendment receives the next consecutive number. |
|
INMM |
Institute of Nuclear Materials Management (United States) |
|
INN |
International Non-proprietary Names |
|
Intended Use |
Objective intent of persons legally responsible for labeling a device. |
|
Investigator IND |
An individual investigator submits a protocol and IND rather than the manufacturer. A letter of authorization allows FDA to review the sponsor’s DMF. The investigator, not the manufacturer, is responsible for maintaining the IND. |
|
INVIMA |
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Columbia) http://www.sinpro.gov.co/invima/indice.htm (in Spanish) |
|
IOL |
Intraocular lens |
|
IPRM |
International Pharmaceutical Regulatory Monitor (journal) |
|
IQ |
Installation Qualification |
|
IRB |
Institutional Review Board or Independent Review Board |
|
IRB |
Institutional Review Board (United States) |
|
IRC |
Institutional Review Committee (United States) |
|
IRF |
International Review Forum (United States) http://www.irf.to |
|
ISAC |
International Society for Analytical Cytology |
|
ISBT |
International Society of Blood Transfusion |
|
ISCVS |
International Society for Cadiovascular Surgery |
|
ISDB |
International Society of Drug Bulletins |
|
ISDN |
Integrated Services Digital Network |
|
ISO |
International Organization for Standardization (not an acronym) |
|
ISO |
International Organization for Standardization |
|
ISPE |
International Society for Pharmaceutical Engineering; International Society for Pharmacoepidemiology |
|
IUO |
Investigational Use Only |
|
IUO |
Investigational Use Only (United States - FDA) |
|
IUPAC |
International Union of Pure and Applied Chemistry |
|
IV |
Intravenous |
|
IVD |
In Vitro Diagnostics |
|
IVD |
In Vitro Diagnostic |
|
IVDAC |
In Vitro Diagnostic Advisory Committee (UK - MDA) |
|
IVDD |
In-Vitro Diagnostic Device Directive (European) |
|
IVDD |
In Vitro Diagnostic Device |
|
IVDP |
In Vitro Diagnostic Product |
|
IVF |
In Vitro Fertilization |
|
IVMP |
|
|
JIT |
Just In Time |
|
JMHW |
Japanese Ministry of Health and Welfare |
|
JPMA |
Japan Pharmaceutical Manufacturers Association (Japan) |
|
JWG |
Joint Working Group (ISO/IEC) |
|
KB |
Kilobyte |
|
KFDA |
Korea Food and Drug Administration (Korea) |
|
Label |
Any display of written, printed or graphic matter on the immediate container or package of, or affixed to, any article. |
|
Labeling |
All written, printed or graphic matter accompanying an article at any time while such article is in interstate commerce or held for sale after shipment in interstate commerce. Includes user manuals, brochures, advertising, etc. |
|
LAL |
Limulus Amebocyte Lysate |
|
LAN |
Local Area Network |
|
LAR |
Laboratory Animal Resources (Korea - NITR) |
|
LBS |
Literature Based Submission (Australia) |
|
LCD |
Liquid Crystal Display |
|
LDPE |
Low density polyethylene |
|
LHF |
Lot History File |
|
LHR |
Lot History Record |
|
LIA |
Laser Institute of America (United States) |
|
LOA |
Letter of Authorization (A letter from the holder of a Drug Master File to FDA, authorizing a company to reference the DMF.) also Letter of Agreement |
|
LOA |
Letter of Authorization (United States - FDA) |
|
LVP |
Large Volume Parenteral (United States) |
|
M2 |
Multidisciplinary Group 2 (ESTRI) of ICH |
|
MA |
Marketing Authorization |
|
MA |
Marketing Authorization |
|
MAC |
Microbiology Advisory Committee (UK - MDA) |
|
MACEAC |
Maximum Allowable Cost-Estimated Acquisition Cost |
|
MAH |
Marketing Authorization Holder |
|
MANSEV |
Market Authorisation by Network Submission and Evaluation (ETOMEP) http://www.jrc.org/isis/etomep/activities/mansev.asp |
|
MAPI |
Mail Application Programming Interface |
|
MAPP |
Manual of Policy and Procedures |
|
Market Withdrawal |
Firm-initiated removal or correction of a device, drug or biologic involving a minor violation of the FD&C Act not subject to legal action by FDA. |
|
MB |
Megabyte |
|
MBM |
Meat and Bone meal (EU) |
|
MCA |
Medicines Control Agency (United Kingdom) http://www.open.gov.uk/mca/homemain.htm |
|
MCA |
Medicines Control Agency (UK) |
|
MCA |
Medicines Control Agency (UK) http://www.open.gov.uk/mca/mcahome.htm |
|
MCH |
Mean Corpuscular Hemoglobin |
|
MCHC |
Mean Corpuscular Hemoglobin Concentration |
|
MCV |
Mean Corpuscular Volume |
|
MDA |